Human papillomavirus type 6 and 11 E6 and E7 oncoproteins (HPV-6/11 E6/E7)

The target "HPV-6/HPV-11 fusion antigen-expressing papilloma cells" refers to host epithelial cells infected with low-risk Human Papillomavirus types 6 or 11 that are actively producing the viral oncoproteins E6 and E7 [3][5]. These cells are the pathological drivers of conditions such as recurrent respiratory papillomatosis (RRP) and condyloma acuminatum (genital warts) [4]. The primary molecular components targeted within these cells are the E6 and E7 proteins, which are often expressed as a synthetic fusion antigen in therapeutic vaccines to enhance immunogenicity [1][2]. E6 and E7 drive the formation of papillomas by interfering with the p53 and pRb tumor suppressor pathways, respectively, leading to abnormal cell growth and evasion of apoptosis [3]. Therapeutic strategies like INO-3107 and PRGN-2012 are designed to prime the immune system to recognize these specific antigens [1][2]. Once activated, cytotoxic T-lymphocytes identify and eliminate the antigen-expressing papilloma cells, thereby clearing the infection and reducing the need for repeated surgical debulking [1][2]. This targeted approach aims to provide long-term immune memory that prevents the recurrence of obstructive or disfiguring lesions [4].

Other names

HPV-6/11 fusion antigenHPV-6/11 oncoproteinsHPV-6/11 E6/E7 expressing cellsLow-risk HPV oncoproteins

Induction of a T-cell mediated immune response (specifically CD8+ cytotoxic T-cells) against cells expressing the HPV-6 and HPV-11 E6 and E7 oncoproteins, leading to the targeted destruction of infected papilloma cells [1][2].